Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company that discovers, develops and commercializes therapeutics for neurological and psychiatric disorders. Its pipeline is led by azetukalner, an investigational Kv7 potassium channel opener being studied in Phase 3 trials for focal onset seizures, primary generalized tonic-clonic seizures, major depressive disorder and bipolar depression. Its early-stage programs include Kv7 potassium channel openers and Nav sodium channel modulators, including candidates being studied for pain and a Nav1.1 program for Dravet syndrome. Xenon also collaborates with Neurocrine Biosciences on sodium channel inhibitors for epilepsy. Under the collaboration, Neurocrine has rights to develop and commercialize compounds including NBI-921352 and other candidates. Xenon’s business includes discovering and advancing its own candidates, partnering on development and commercialization, and potentially commercializing products alone or with collaborators. Xenon is headquartered in Burnaby.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $XENE in the last 30 days.
See all $XENE insider activity →Analysts from Wells Fargo and Bank of America Securities provided ratings and price targets for Xenon (XENE), Veeva Systems (VEEV), and Liquidia Technologies (LQDA). Xenon received a Buy rating with a $64 target, Veeva a Buy with a $400 target, and Liquidia a Hold with a $54 target. Consensus ratings and targets also provided.
Xenon Pharmaceuticals reported Q3 updates, highlighting its epilepsy drug AZK's success in clinical trials, with a 42.7% median reduction in seizures. The company plans to start a phase IIIb/IV study in 2027 and is preparing for commercial launch. Xenon also expects to initiate phase II studies for pain candidates XEN1701 and XEN1120 in early 2027. With $1.2 billion in cash, the company's runway extends into 2029.
Xenon Pharmaceuticals Inc. (XENE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Xenon Reports Q3 2026 Financial Results and Provides Business Update • New Drug Application for azetukalner in focal seizures submitted to U.S. Food & Drug Administration in September 2026 • Expanding potential opportunity in epilepsy through ongoing Phase 3 X-TOLE3
Over the past 7 days, AlphAI's AI scored 7 news stories mentioning XENE (Xenon Pharmaceuticals Inc.). Coverage has skewed bullish: 4 bullish, 2 neutral, and 1 bearish.
Recent XENE coverage spans financial news, technology and earnings.
Analyst coverage suggests upside potential.
Positive trial data may lift the stock; ample cash reduces financing risk.
Positive clinical updates and NDA filing suggest near‑term upside potential.
The grant creates modest dilution and adds compensation expense, likely exerting slight downward pressure on the stock.
Positive early‑stage data should lift sentiment and may drive short‑term buying pressure.
AlphAI scores every news story that mentions XENE with an AI model for sentiment and relevance, and aggregates insider trades from Xenon Pharmaceuticals Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Analysts from Wells Fargo and Bank of America Securities provided ratings and price targets for Xenon (XENE), Veeva Systems (VEEV), and Liquidia Technologies (LQDA). Xenon received a Buy rating with a $64 target, Veeva a Buy with a $400 target, and Liquidia a Hold with a $54 target. Consensus ratings and targets also provided.
Xenon Pharmaceuticals reported Q3 updates, highlighting its epilepsy drug AZK's success in clinical trials, with a 42.7% median reduction in seizures. The company plans to start a phase IIIb/IV study in 2027 and is preparing for commercial launch. Xenon also expects to initiate phase II studies for pain candidates XEN1701 and XEN1120 in early 2027. With $1.2 billion in cash, the company's runway extends into 2029.
Xenon Pharmaceuticals Inc. (XENE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Xenon Reports Q3 2026 Financial Results and Provides Business Update • New Drug Application for azetukalner in focal seizures submitted to U.S. Food & Drug Administration in September 2026 • Expanding potential opportunity in epilepsy through ongoing Phase 3 X-TOLE3
Xenon Pharmaceuticals (XENE) granted equity inducements to nine new employees, including 24,250 share options and 14,250 RSUs. Options have a $37.54 exercise price, vest over four years, and expire in 10 years. RSUs vest over four years. Grants were approved by the Board's Compensation Committee.
Xenon Pharmaceuticals (NASDAQ:XENE) reported positive Phase 1 results for two pain treatments, XEN1701 and XEN1120, with plans for Phase 2 trials in 2027. XEN1701 showed over 75% receptor occupancy, while XEN1120 reached predicted analgesic plasma levels. Common adverse events included headache, dizziness, and tachycardia. Data were presented at a pain congress in Bangkok.
Insiders at Oracle (ORCL) and Xenon Pharmaceuticals (XENE) made significant stock purchases, indicating confidence. ORCL reported strong Q1 earnings with 30% YoY revenue growth, driven by cloud services. XENE submitted an NDA for its epilepsy drug but paused trials for depression treatments. Analysts rate both stocks as Strong Buys with over 60% upside potential.
Xenon Pharmaceuticals' President Ian Mortimer bought US$1.1m worth of stock at US$37.38 per share, increasing his holding by 88%. This is the largest insider purchase in the past year, with insiders buying more shares than they sold. Insiders own 0.1% of the company, worth US$4.4m. The company is currently loss-making.
Xenon Pharmaceuticals (XENE) saw insider buying of $1.68M, with CEO and CFO purchasing shares. The company's lead drug, Azetukalner, is under FDA review for epilepsy. XENE shares rose 5%, their best day in over a month. The company has no revenue and a net loss of $110.7M in Q2, but holds $1.25B in cash.
Kelly Thomas Patrick (Chief Financial Officer) purchased 15,000 shares of Xenon Pharmaceuticals Inc. (XENE) at $37.32 ($0.56M total) on 2026-09-30.
Xenon Pharmaceuticals' CEO Ian Mortimer bought 30,000 shares at $37.38 each, totaling $1.12M. He now directly owns 49,923 shares and indirectly owns 14,300 via spouse, according to an SEC filing.
